Search research articles
Contact Us
Filters
Showing results (1-10 of 22) with videos related to
Page
of 3
Sort By:
American Journal of Therapeutics
|
June 28, 2013
Progress in the treatment of peripheral T-cell lymphomas: an orphan no more
Ronald Lieberman
World Journal of Urology
|
April 19, 2003
Evolving strategies for prostate cancer chemoprevention trials
Ronald Lieberman
American Journal of Therapeutics
|
March 8, 2013
The androgen receptor, androgen synthesis, and new designer antiandrogens for metastatic castration-resistant prostate cancer: teaching old dogs new tricks
Ronald Lieberman
Cancer Metastasis Reviews
|
January 29, 2003
Chemoprevention of prostate cancer: current status and future directions
Ronald Lieberman
American Journal of Therapeutics
|
October 16, 2009
Personalized medicine enters the US marketplace: KRAS, anti-EGFR monoclonal antibodies, and colon cancer
Ronald Lieberman
American Journal of Therapeutics
|
September 27, 2012
Food and Drug Administration approval of cetuximab and a new KRAS genetic test for metastatic colorectal cancer: major advance but just the tip of the biomarker iceberg
Ronald Lieberman
American Journal of Therapeutics
|
November 16, 2004
Evidence-based medical perspectives: the evolving role of PSA for early detection, monitoring of treatment response, and as a surrogate end point of efficacy for interventions in men with different clinical risk states for the prevention and progression of prostate cancer
Ronald Lieberman
Archives of Physical Medicine and Rehabilitation
|
November 5, 2003
Fluoroscopically guided interlaminar cervical epidural injections
Ronald Lieberman, Paul Dreyfuss, Ray Baker
Oncology (Williston Park, N.Y.)
|
September 12, 2003
Clinical trials referral resource. Current NCI-sponsored clinical trials in prostate cancer: prevention, treatment, supportive care, and imaging
Alison Martin, Ronald Lieberman, Howard Parnes, et al.
The Journal of Urology
|
January 10, 2004
Prostate cancer chemoprevention agent development: the National Cancer Institute, Division of Cancer Prevention portfolio
Howard L Parnes, Margaret G House, Jacob Kagan, et al.
Page
of 3
Search research articles
Search
Showing results (1-10 of 22) with videos related to
Sort By:
Page
of 3
American Journal of Therapeutics
|
June 28, 2013
Progress in the treatment of peripheral T-cell lymphomas: an orphan no more
Ronald Lieberman
World Journal of Urology
|
April 19, 2003
Evolving strategies for prostate cancer chemoprevention trials
Ronald Lieberman
American Journal of Therapeutics
|
March 8, 2013
The androgen receptor, androgen synthesis, and new designer antiandrogens for metastatic castration-resistant prostate cancer: teaching old dogs new tricks
Ronald Lieberman
Cancer Metastasis Reviews
|
January 29, 2003
Chemoprevention of prostate cancer: current status and future directions
Ronald Lieberman
American Journal of Therapeutics
|
October 16, 2009
Personalized medicine enters the US marketplace: KRAS, anti-EGFR monoclonal antibodies, and colon cancer
Ronald Lieberman
American Journal of Therapeutics
|
September 27, 2012
Food and Drug Administration approval of cetuximab and a new KRAS genetic test for metastatic colorectal cancer: major advance but just the tip of the biomarker iceberg
Ronald Lieberman
American Journal of Therapeutics
|
November 16, 2004
Evidence-based medical perspectives: the evolving role of PSA for early detection, monitoring of treatment response, and as a surrogate end point of efficacy for interventions in men with different clinical risk states for the prevention and progression of prostate cancer
Ronald Lieberman
Archives of Physical Medicine and Rehabilitation
|
November 5, 2003
Fluoroscopically guided interlaminar cervical epidural injections
Ronald Lieberman, Paul Dreyfuss, Ray Baker
Oncology (Williston Park, N.Y.)
|
September 12, 2003
Clinical trials referral resource. Current NCI-sponsored clinical trials in prostate cancer: prevention, treatment, supportive care, and imaging
Alison Martin, Ronald Lieberman, Howard Parnes, et al.
The Journal of Urology
|
January 10, 2004
Prostate cancer chemoprevention agent development: the National Cancer Institute, Division of Cancer Prevention portfolio
Howard L Parnes, Margaret G House, Jacob Kagan, et al.
Page
of 3